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To delineate the role of plasmin inhibitors, especially the
two molecular forms of ll'2-antiplasmin (that is, the plas-
minogen-binding and the nonplasminogen-binding forms),
in the control of systemic effects during thrombolytic ther·
apy, the consumption of plasmin inhibitors and the degree
of fibrinogen breakdown were studied in 35 patients with
acute myocardial infarction treated with recombinant tis-
sue·type plasminogen activator (rt-PA) or streptokinase.
At a low degree of plasminogen activation (in six pa·
tients treated with rt-PA), plasminogen-binding ll'2'
antiplasmin was consumed first. At a higher degree of
plasminogen activation (in 20 patients), plasminogen-
binding ll'2·antiplasmin became exhausted «20%) and
other plasmin inhibitors (that is, nonplasminogen-binding
ll'2-antiplasmin and ll'2-macroglobulin) were consumed. Af-
ter extensive plasminogen activation (in nine patients
treated with streptokinase), plasminogen-binding ll'2-
antiplasmin consumption was complete and nonplasmino-
gen.binding urantiplasmin and urmacroglobulin were
Thrombolytic therapy with plasminogen activators is becom-
ing an accepted treatment for patients with acute myocardial
infarction. Other diseases involving a pathologic thrombus,
such as venous thrombosis (1,2), thrombotic stroke (3,4),
pulmonary embolism (5,6) and several other conditions (7),
are also increasingly subject to thrombolytic treatment.
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consumed to about 30% to 50% of the pretreatment level.
No significant C.-inactivator consumption occurred, even
at extreme degrees of plasminogen activation.
Fibrinogen breakdown as a marker for systemic effects
correlated strongly with consumption of plasminogen-
binding ll'2-antiplasmin. Fibrinogen breakdown did occur,
but only when the amount of plasminogen-binding ll'z-
antiplasmin was decreased to <20% of the pretreatment
level. The other plasmin inhibitors could not prevent fibrin-
ogen breakdown. These results were confirmed by in vitro
studies.
It is concluded that plasminogen.binding ll'z-antiplasmin
is the most important inhibitor of plasmin in the circula-
tion. To obtain systemic effects, the amount of plasmino-
gen-binding ll'z-antiplasmin, which is a threshold in the
circulation, has to be overcome. This indicates that plas-
minogen-binding ll'z·antiplasmin may be a new marker to
predict systemic effects during thrombolytic therapy.
(J Am Coil CardioI1990;15:1212-20)
, Several thrombolytic agents have been studied and are in
use. They include streptokinase, anisoylated plasminogen
streptokinase activator complex (APSAC), recombinant tis-
sue-type plasminogen activator (rt-PA) and pro-urokinase.
One main difference among these frequently used throm-
bolytic agents is the degree of fibrin specificity and the
degree of systemic effects at effective dosages. Roughly, two
categories of lytic agents can be distinguished: streptoki-
nase, APSAC and urokinase, which are associated with
more extensive systemic effects, and rt-PA and pro-
urokinase. which are associated with a lesser degree of
systemic lytic effects (8).
The systemic effects concern, among other things, diges-
tion of fibrinogen, resulting in appearance of (anticoagulant)
split products (9). and of coagulation factors V and VIII
(l0, II). This degradation of factors is a result of the proteo-
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lytic action of plasmin formed from plasminogen in large
amounts by the thrombolytic agents (12). More recently,
other effects of such excessive plasmin formation have also
been described (13,14). It has been shown (13) that plasmin-
ogen activation at the platelet surface leads to degradation of
glycoprotein Ib and the lIb/IlIa complex, which inhibits
platelet adhesion and aggregation. In addition, platelet mass
may dissolve because of the proteolytic effect of plasmin on
thrombospondin (14).
The significance of systemic effects in thrombolytic ther-
apy has not been satisfactorily clarified. It has been sug-
gested that the systemic effects constitute a disadvantage
and may contribute to bleeding, which is the main side effect
of thrombolytic treatment (15-18). However, data that show
opposing findings have also been published (19,20). Alterna-
tively, it has been suggested that the systemic effects may be
beneficial, for instance in attaining recanalization (1 L21). It
has even been proposed (22) that systemic effects and
recanalization must correlate because of the key role of
plasmin. In addition, the proteolytic damage of plasmin
improves rheology of blood (23,24) and results in impairment
of the coagulation system, thereby reducing the risk of
rethrombosis. Therefore, further study on the occurrence
and clinical significance of systemic effects is required.
Because plasmin is the key enzyme in fibrinolysis and is
responsible for the systemic effects, plasmin inhibitors may
have a regulatory role in both processes. Several inhibitors
of plasmin circulate in blood: u2-antiplasmin, u2-macroglob-
ulin, CI-inactivator and ul-antitrypsin. The two functional
forms of u2-antiplasmin (the main inhibitor of plasmin),
namely, the plasminogen-binding and the nonplasminogen-
binding forms, are present in the circulation in a concentra-
tion of 0.7 and OJ /LM, respectively (25). In vitro experi-
ments (26) in purified systems have shown that these two
forms have a different mechanism of plasmin inhibition.
Plasminogen-binding urantiplasmin, which is the most ac-
tive form, inhibits plasmin by rapid formation of an irrevers-
ible 1: 1 stoichiometric complex (27). The function of non-
plasminogen-binding u2-antiplasmin is still unclear. In vitro
studies (26) have shown that it is less active than plasmino-
gen-binding u2-antiplasmin and that complex formation with
plasmin proceeds more slowly. Recent developments in the
assay of u2-antiplasmin have made it possible to determine
the two molecular forms separately. This separate assess-
ment of plasminogen-binding and nonplasminogen-binding
u2-antiplasmin may give information on the consumption of
the two forms of urantiplasmin during thrombolytic ther-
apy.
The aim of our study was to delineate the role of plasmin
inhibitors in the control and prevention of systemic effects,
utilizing fibrinogen breakdown as a marker. We investigated,
both in vivo and in vitro, one representative agent from each
of the two groups of thrombolytic agents with different
systemic effects (for example, rt-PA and streptokinase).
Methods
Study patients. We studied the relation between the
consumption of plasmin inhibitors and extent of fibrino-
genolysis in 35 patients with acute myocardial infarction
who were receiving thrombolytic treatment. These patients
were participating in clinical studies in the United King-
dom and The Netherlands. Before patients entered these
studies, informed consent was obtained from the patients
or relatives, and research was carried out according to
the principles of the Declaration of Helsinki (28,29). The
selection criteria for both studies are described in detail
elsewhere (28,29). Nine patients were treated with streptoki-
nase (Kabikinase, KabiVitrum Haematology, Stockholm,
Sweden) at a dose of 0.2 to 3.0 x 106 IV infused intrave-
nously over 60 min. Twenty patients were treated with
100 mg of recombinant tissue-type plasminogen activator
(rt-PA) (BW-t-PA, Wellcome, Beckenham, United King-
dom) infused intravenously over 90 min. In addition, six
patients received either 20 mg (n == 4) or 50 mg (n == 2) of
rt-PA.
Plasma samples. Blood samples of the patients with acute
myocardial infarction were taken just before and at the end
of the infusion (t == 60 min for streptokinase or 90 min for
rt-PA). Venous blood was collected in trisodium-citrate
(9:1 volume for volume) and immediately placed on melting
ice. Plasma was prepared by centrifugation at 2,000 g for 30
min at 4°C and frozen in small aliquots at -70°C. It was
thawed at 37°C immediately before use. To exclude plasmi-
nogen activation in vitro, inhibitory polyclonal t-PA antibod-
ies (250 /Lg) were added immediately after obtaining plasma
from the patients treated with rt-PA (30). Pooled normal
plasma was obtained from 20 healthy volunteers (1: I male/
female ratio).
Plasma artifically depleted in plasminogen-binding U2-
antiplasmin was obtained by affinity chromatography of
pooled plasma depleted in plasminogen (by chromatography
on lysine-Sepharose [31]) on Kringle 1-I1I-Sepharose. Frac-
tions of 4 ml were collected. The fractions with the highest
A2so (protein concentration) were pooled and, after dialysis,
concentrated to the original plasma volume. Before incuba-
tion experiments, plasminogen was added to the plasma to a
final concentration equal to that of pooled normal plasma.
Assays. The concentrations of the plasminogen-binding
and nonplasminogen-binding forms of u2-antiplasmin were
determined by modified crossed immunoelectrophoresis. This
technique was described in detail by Kluft and Los (32). In
brief, plasminogen is added to the first dimension gel, result-
ing in reduction of electrophoretic mobility of plasminogen-
binding u2-antiplasmin. Nonplasminogen-binding u2-antiplas-
min retains its normal mobility, and the two forms can be
determined separately (Fig. 1). Before second dimension
electrophoresis, an intermediate gel containing 2% antiserum
against lys-plasminogen (a gift from Dr. D. W. Traas from the
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zation purposes, modified crossed immunoelectrophoresis of
plasma before and after treatment in one patient was done
under identical conditions on one glass plate. By measuring
the surface of the immunoprecipitation peaks before (pre-
treatment level is 100%) and after thrombolytic treatment, it
is possible to determine the consumption of both forms of
£I'2-antiplasmin. A vague peak (arrow, Fig. 1) was seen on
modified crossed immunoelectrophoresis, most likely repre-
senting degradation products of £I'z-antiplasmin that do not
disturb the determination of the two forms. The variation
coefficient of this assay was 2.5% using the polyclonal
anti-£I'2-antiplasmin antiserum from Nordic Immunology in
the second dimension gel, and 5.9% using another antiserum
(Stago, Asnieres, France).
£I'rAntiplasmin activity was measured with a modified
immediate plasmin inhibition test (33). This assay is based on
the rapid inactivation of plasmin by £I'z-antiplasmin, thereby
reducing the influence of other plasmin inhibitors. In this
assay, an excess of plasmin is added to the patient's plasma,
after which complex formation between plasmin and £1'2-
antiplasmin occurs. The residual plasmin activity is a marker
for the concentration of £I'2-antiplasmin in plasma, and is
measured using the synthetic chromogenic substrate S-2251.
The variation coefficient of this test was 2.9%.
£I'rMacroglobulin antigen levels were assayed according
to the method of Laurell (34), using a 2% anti-£I'z-
macroglobulin antiserum from Nordic Immunology. C1-
inactivator was measured by a single radioimmunodiffusion
technique (35), using an anti-C,-inactivator antiserum from
Behringwerke (Marburg, FRG). Plasminogen was measured
according to the method of Friberger et al. (36), using
Kabikinase (streptokinase) for activation of plasminogen and
S-2251 as a substrate, both from KabiVitrum Haematology).
Fibrinogen was measured using a clot rate assay (37).
Total (fibrin and fibrinogen) degradation products were mea-
sured using an enzyme-linked immunosorbent assay
(ELISA) technique, with a monoclonal antibody (FDP-14)
against a neoantigenic determinant in fragment E as the
catching antibody and monoclonal antibodies to D-dimer
(DD-13) and to fragments holding fibrinopeptide A (Y-18) as
the tagging antibodies (Organon Teknika, Boxtel, The Neth-
erlands) (38). The variation coefficient of this test was 12%.
In vitro studies. In vitro studies were performed by
addition of different doses of streptokinase (Kabikinase) or
single chain melanoma rt-PA (39) to pooled plasma with
incubation for 90 min at 37°C. The doses of streptokinase
and single chain rt-PA added to pooled plasma varied from 5
to 1,000 and 60 to 9,000 IV/ml, respectively.
Statistical evaluation. Wilcoxon and Spearman rank sum
tests were used for statistical analysis. A p value of <0.05
was considered to be significant. Unless otherwise stated,
data are given as median and range.
PLG
anti·PLG
anti-PLG
PLG
anti ~-AP
before t-PA treatment
anti-a -AP
2
Figure 1. Modified crossed immunoelectrophoresis of plasma from
a patient with acute myocardial infarction, before (top) and after
(bottom) treatment with 100 mg of recombinant tissue-type plasmin-
ogen activator (t-PA). The consumption of both forms of 0z-
antiplasmin (oz-AP) is measured by calculating the difference be-
tween the surface of the immunoprecipitation peaks before and after
treatment. The arrow indicates a vague peak, probably representing
degradation products of oz-antiplasmin. anti-PLO = gel containing
antibodies against plasminogen; NPB = nonplasminogen-binding
form of oz-antiplasmin; PH = plasminogen-binding form of 0z-
antiplasmin; PLO = plasminogen.
Gaubius Institute) was poured to capture and precipitate
plasmin £I'z-antiplasmin complexes. The gel for the second
dimension contained 1.5% rabbit antihuman £I'z-antiplasmin
antiserum (Nordic Immunology, Tilburg, The Netherlands).
Trasylol (1,000 kIV/mO (Bayer, Leverkusen, FRG) was
added to the agarose to inhibit proteolytic activities.
The concentrations of the plasminogen-binding and non-
plasminogen-binding forms of £I'z-antiplasmin were deter-
mined by measuring the immunoprecipitation peaks with a
computerized program using a Hipad digitalizer (Geveke
Electronics, Amsterdam, The Netherlands). For standardi-
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Figure 2. The levels of plasminogen, a2-antiplasmin (a2-AP) activity
and the plasminogen-binding (PB) and nonplasminogen-binding
(NPB) forms of a2-antiplasmin (AP) for all nine patients with acute
myocardial infarction before (B) and after (A) streptokinase treat-
ment. Results are expressed as a percent of normal pooled plasma.
The values of both forms of a2-antiplasmin are expressed as a
percent of pretreatment levels. After treatment, plasminogen-
binding a2-antiplasmin was totally consumed in all nine patients.
Therefore, one data point representing all individuals is given in the
figure.
Results
In Vivo Studies
£t'rAntiplasmin consumption during streptokinase treat-
ment (Fig. 2). Nine patients with acute myocardial infarc-
tion treated with a wide range of streptokinase dosages were
studied. Treatment involved 0.2 x 106 (n = 1), 0.75 X 106
(n = 4), 1.5 X 106 (n = 3) and 3.0 x 106 IV (n = 1) over 60
min. A strong decline in plasminogen (from 94% [range 74 to
111] to 6% [range 2 to 49]) was found in all patients. The
rapid plasmin inhibitory capacity (a2-antiplasmin activity
level) decreased from 102% (range 83 to 129) to 11% (range
4 to 28). The consumption of plasminogen-binding a2-
antiplasmin was complete in all patients. Nonplasminogen-
binding a2-antiplasmin decreased to 57% (range 36 to 72) of
the pretreatment level. The concentration of a2-macroglob-
ulin decreased from 83% (range 60 to 145) to 46% (range 33
to 85), whereas CI-inactivator did not decrease (from 97%
[range 89 to 103] to 95% [range 86 to 111]). In all patients
treated with streptokinase, practically all circulating fibrin-
ogen was degraded, independent of the pretreatment levels
of fibrinogen (mean pretreatment level 85% (range 54 to 104),
not shown), The levels of fibrin(ogen) degradation products
after treatment with streptokinase was 124 JLg/ml (range 6 to
270).
Therefore, despite the wide range of streptokinase dos-
ages, patients treated with streptokinase demonstrate a
Figure 3. The levels of plasminogen, a2-antiplasmin (a2-AP) activity
and the plasminogen-binding (PB) and the nonplasminogen-binding
(NPB) forms of a2-antiplasmin for the 20 patients with acute
myocardial infarction before (B) and after (A) treatment with 100 mg
of rt-PA. Results are expressed as a percent of normal pooled
plasma. The values of the two a2-antiplasmin forms are given as a
percent of pretreatment levels.
homogeneous response in the consumption of plasminogen-
binding a2-antiplasmin (complete), degradation of fibrinogen
(complete) and consumption of CI-inactivator. Nonplasmin-
ogen-binding a2-antiplasmin and a2-macroglobulin are only
partially consumed.
£t'2-Antiplasmin consumption during rt-PA treatment (Fig.
3). Twenty patients with acute myocardial infarction treated
with 100 mg of rt-PA (over 90 min) demonstrated less
consumption of plasminogen and plasmin inhibitors than
patients treated with streptokinase. The plasminogen con-
centration decreased from 104% (range 70 to 134) before
treatment to 75% (range 59 to 97) after treatment. a2-
Antiplasmin activity decreased from 97% (range 76 to 129)
before treatment to 33% (range 7 to 84) after treatment. The
predominant consumption of a2-antiplasmin mainly con-
cerned the plasminogen-binding form of az-antiplasmin (Fig.
1). Among the 20 patients treated with rt-PA, total consump-
tion of plasminogen-binding Qz-antiplasmin was observed in
only 1, and the residual plasminogen-binding az-antiplasmin
level was 15% (range 0 to 39) of the pretreatment level.
Nonplasminogen-binding az-antiplasmin decreased only
slightly to 88% (range 60% to 100%) of the pretreatment
level. az-Macroglobulin and C,-inactivator levels did not
show a significant decrease in rt-PA-treated patients. The
pretreatment levels for az-macroglobulin and CJ-inactivator
were 89% (range 60% to 119%) and 95% (range 54 to 162),
respectively. The posttreatment levels were 78% (range 52%
to 105%) and 88% (range 46% to 115%), respectively.
Fibrinogen levels in patients after treatment with rt-PA
varied strongly from a 31% increase of fibrinogen in only one
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Discussion
All thrombolytic agents now in use show systemic effects
at clinically effective doses. However, the degree of sys-
Figure 4. The relative breakdown of fibrinogen plotted against the
consumption of the plasminogen-binding form of a2-antiplasmin
(PB-a2-AP) for all patients with acute myocardial infarction receiv-
ing thrombolytic treatment. A strong correlation between consump-
tion of plasminogen-binding a2-antiplasmin and the percent break·
down of fibrinogen was found (r = 0.88, P < 0.001). 0 = various
doses of streptokinase; • = 100 mg of rt-PA; * = 50 mg of rt-PA;
o = 20 mg of rt-PA.
was preferentially consumed; nonplasminogen-binding Q!2'
antiplasmin was consumed only at higher dosages of strep-
tokinase. Maximal consumption of nonplasminogen-binding
Q!2-antiplasmin stabilized at about 50%, even after addition of
very high doses of streptokinase, which coincided with
depletion of plasminogen. In these in vitro experiments, no
fibrinogen breakdown occurred until plasminogen-binding
Q!2·antiplasmin was reduced to <20% to 25% of the initial
level. Addition of even very low doses (10 IU/ml) of strep-
tokinase to plasma artificially depleted in plasminogen-
binding Q!2-antiplasmin resulted in the breakdown of all
fibrinogen.
Single chain rt-PA (Fig. 6). Incubation of plasma with
single chain rt-PA showed the same pattern as with strep-
tokinase. However, extremely high doses of single chain
rt-PA were required to achieve consumption of nonplasmin-
ogen-binding Q!2-antiplasmin. Further, these incubation ex-
periments showed that fibrinogen breakdown occurred after
a plasminogen-binding Q!2-antiplasmin reduction of ::;25%.
Accordingly, incubation of plasminogen-binding Q!2-
antiplasmin-depleted plasma with low doses of single chain
rt-PA (600 mIU/m!) resulted in the consumption of all
fibrinogen.
patient to a maximal breakdown of 79%. The median fibrin-
ogen breakdown was 26% of the pretreatment plasma level.
The median level of fibrin(ogen) degradation products after
treatment with 100 mg ofrt-PA was 3.1 p,g/ml (range 0.5 to
19.2). Thus, despite the fixed dosage of rt-PA studied, the
systemic effects as derived from fibrinogen breakdown are
strongly variable. Furthermore, the consumption of plasmin-
ogen-binding Q!2-antiplasmin and plasminogen varied consid-
erably among patients.
Variability in fibrinogen degradation in rt-PA-treated pa-
tients. In investigating the reason for the variability in
fibrinogen degradation in the rt-PA-treated patients, we
explored correlations with endogenous fibrinolytic variables
among the patients. A correlation was found between the
extent of fibrinogen breakdown and the pretreatment con-
centrations of fibrinogen (r == 0.59, p < 0.01) and plasmino-
gen (r == 0.55, p < 0.02). No significant correlation was found
between the extent of fibrinogen breakdown and the pre-
treatment levels of Q!2-antiplasmin (r == 0.38). Q!rmacroglob-
ulin (r == -0.05) and CI-inactivator (r == -0.18). The con-
sumption of plasminogen, as a percent of the pretreatment
value (r == 0.58, p < 0.01) and Q!2-antiplasmin (r == 0.55, P <
0.01), also correlated with the extent of fibrinogen break-
down, but the correlation with the lowest p value was found
between the consumption of the plasminogen-binding form
of Q!2-antiplasmin and the amount of fibrinogenolysis (r ==
0.68, p < 0.002).
To investigate further the apparent relation between
plasminogen-binding Q!rantiplasmin consumption and fi-
brinogen breakdown, we measured the consumption of
plasminogen-binding Q!rantiplasmin and fibrinogen levels in
patients who were treated with low doses of rt-PA (Fig. 4).
The less extensive activation of the fibrinolytic system in
these patients was reflected by a lower consumption of
plasminogen-binding Q!rantiplasmin and fibrinogen. As al-
ready mentioned, in the streptokinase-treated patients, all
plasminogen-binding Q!rantiplasmin was consumed, along
with a total breakdown of fibrinogen, as determined by the
method of Clauss (37). The correlation of plasminogen-
binding Q!rantiplasmin consumption and fibrinogen con-
sumption in all 35 patients with acute myocardial infarction
who were treated with plasminogen activators (both strep-
tokinase and rt-PA) was highly significant (r = 0.88, p <
0.001).
In 11itro Studies
Streptokinase (Fig. 5). To investigate whether the find-
ings in the patients receiving thrombolytic therapy could be
confirmed in vitro, we incubated pooled normal plasma with
streptokinase and single chain rt-PA. Incubation of pooled
normal plasma with streptokinase resulted in a strong plas-
minogen activation and a decrease in both Q!2-antiplasmin
forms. At low dosages, plasminogen-binding Q!2-antiplasmin
consumption
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Figure 5. Results of the in vitro experiments with
streptokinase. Experiments were performed by addition
of various doses of streptokinase to normal pooled
plasma, with incubation for 90 min at 37°C. Abbrevia·
tions as in Figure 1.
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temic effects is strongly variable. This may be caused by
differences in fibrin specificity of the various agents, but
differences in endogenous (fibrinolytic) factors may also
contribute to the variability in systemic effects.
The aim of our study was to delineate the role of
endogenous factors (in particular, physiologic inhibitors of
plasmin) in controlling systemic effects during thrombolytic
therapy. We therefore investigated both the degree of con-
sumption of various plasmin inhibitors and the degree of
fibrinogen breakdown by activating plasminogen in plasma
in vivo and in vitro. This was carried out first in patients with
acute myocardial infarction, treated with various doses of
different thrombolytic agents, and then in vitro experiments
in which plasma was incubated with various amounts of
thrombolytic agents.
Methods used in the study. For the quantification of
O!z-antiplasmin consumption, we studied for the first time the
two molecular forms of O!z·antiplasmin separately, by using
modified crossed immunoelectrophoresis (36). Most of the
activity assays for O!z·antiplasmin currently used are not
specific for one of the two forms, and instead measure both
forms. In addition, these methods are frequently disturbed
by the presence of other plasmin inhibitors (for instance,
O!z·macroglobulin). In an immunologic assay (as in crossed
immunoelectrophoresis), the presence of plasmin-O!z-
antiplasmin complexes in plasma may disturb in vitro stud-
ies, but may also disturb in vivo studies because ofthe rather
long half-life of about 12 h of the complexes in the circulation
(40). By using an intermediate gel containing antiplasmino-
gen antibodies to capture and precipitate these complexes, it
Figure 6. Results of the in vitro experiments with single
chain rt-PA. Experiments were performed by addition
of various doses of single chain rt-PAto normal pooled
plasma, with incubation for 90 min at 37°C. Abbrevia-
tions as in Figure 1.
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was possible to study the consumption of both forms of
l¥z-antiplasmin. l¥rMacroglobulin levels were determined
only in vivo by immunoelectrophoresis (34), which was not
disturbed by the presence of plasmin-l¥z-macroglobulin com-
plexes because of the rapid clearance of the latter from the
circulation (41).
Fibrinogen consumption was recorded by the Clauss
clotting rate assay (37). This assay can be disturbed by high
levels of fibrin(ogen) degradation products, which occurred
in the patients treated with streptokinase. However, in the
patients treated with rt-PA, the total amount of split prod-
ucts was small and outside the range that affects the Clauss
method. This was confirmed in the plasma sample with the
highest levels of fibrin(ogen) degradation products in one
patient. At the dilution used in the Clauss assay, the dose-
response curve of this plasma was parallel to the standard
curve (data not shown).
The low levels of./ibrin(ogen) degradation products in the
plasma samples of the patients treated with rt-PA may be
due to the addition of polyclonal antibodies against rt-PA
immediately after obtaining plasma to prevent fibrinogen
breakdown in vitro. The results are, therefore, repre-
sentative for the actual situation in vivo.
Levels of plasmin inhibitors during thrombolysis. The
studies in patients treated with rt-PA and streptokinase and
the incubation experiments in vitro had similar results.
Activation of plasminogen results first in the consumption of
plasminogen-binding l¥rantiplasmin only, without any role
for nonplasminogen-binding l¥z-antiplasmin and l¥Z-
macroglobulin. This was demonstrated in some patients
treated with 100 mg ofrt-PA and patients treated with lower
doses of rt-PA. This finding is in accordance with previous
studies (42), in which l¥z-macroglobulin was found to play
only a minor role in plasmin inhibition as long as l¥Z-
antiplasmin was present in the circulation. Higher degrees of
plasminogen activation in the rt-PA-treated patients resulted
in the exhaustion of plasminogen-binding l¥z-antiplasmin
«20%) and consumption of nonplasminogen-binding l¥z-
antiplasmin and l¥z-macroglobulin. After extensive plasmin-
ogen activation, as in patients treated with streptokinase, the
consumption of plasminogen-binding l¥z-antiplasmin was
complete and consumption of both nonplasminogen-binding
l¥z-antiplasmin and l¥z-macroglobulin was partial. The con-
sumption of nonplasminogen-binding l¥z-antiplasmin
amounted to about 50% (0.15 p,M) and of l¥z-macroglobulin
to about 30% (1.0 p,M) of pretreatment levels. This indicates
that both inhibitors are equally effective, but that because of
its higher concentration, l¥z-macroglobulin binds more plas-
min.
The consumption of both inhibitors is only partial be-
cause of an excess of the inhibitors over the amount of
plasminogen available for activation (Fig. 7). Accordingly,
we found an increased consumption of nonplasminogen-
binding l¥rantiplasmin in vitro when the plasminogen con-
3.0
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Figure 7. Average plasma concentration (in JLM) of plasminogen
(PLO) and plasmin inhibitors in normal individuals before treatment
with plasminogen activators (black bars). The open bars indicate
maximal consumption of plasminogen and the plasmin inhibitors
after excessive plasmin formation, as was the case in the patients
treated with streptokinase. In plasma, plasminogen is present at
twice the concentration of the plasminogen-binding form of cx2-
antiplasmin. cx2-M == cx2-macroglobulin; CeI == C[-inactivator; NPB-
cx2-AP == non-plasminogen-binding cx2-antiplasmin; PB-cx2-AP ==
plasminogen-binding cx2-antiplasmin.
sumption was increased by addition of exogenous plasmino-
gen to the test plasma (data not shown). We also
demonstrated for the first time that nonplasminogen-binding
l¥z-antiplasmin inhibits plasmin in vivo. There was no C1-
inactivator consumption in our study at any degree of
plasminogen activation, and C\-inactivator seemed to play
no important role in plasmin inhibition in vivo.
Relation between plasmin inhibition and fibrinogen break-
down. The pattern of fibrinogen degradation during plasmin-
ogen activation was similar both in vivo and in vitro. Both
types of study revealed that fibrinogen consumption was
strongly correlated with the consumption of plasminogen-
binding l¥z-antiplasmin. Fibrinogen breakdown occurred
only when >80% of the plasminogen-binding l¥z-antiplasmin
was consumed. The fact that other plasmin inhibitors in
plasma were stilI present in a concentration of 50% to 90% of
the pretreatment level, even at the highest degree of plas-
minogen activation, indicates the minor importance of these
inhibitors in preventing systemic effects. It also suggests that
only plasminogen-binding l¥z-antiplasmin plays an important
role in the control and prevention of systemic effects of
plasmin in the circulation and that the amount of plasmino-
gen-binding l¥z-antiplasmin seems to be a threshold that has
to be overcome to obtain systemic effects. Plasminogen-
binding l¥2-antiplasmin may therefore be used as a new
marker to predict systemic effects during thrombolytic ther-
apy. It seems more rational to use the plasminogen-binding
l¥z-antiplasmin level because it is the primary variable that
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decreases after plasmin formation as a result of the fast
formation of plasmin-lXz-antiplasmin complexes. Fibrinogen
is the secondary variable that decreases as a result of the
proteolytic action of free plasmin in the circulation. In
contrast, fibrinogen levels may be more easily determined.
However, various fibrinogen assays, such as clotting rate
assays or assays using alkaline precipitation, are in use. In
this study, a clotting rate assay was used, which is consid-
ered to be a functional assay for fibrinogen during throm-
bolytic therapy (43). Other assays using alkaline precipita-
tion may give other results. Although the assay we used to
study both forms of lXz-antiplasmin is useful, it is very
complicated. At present, we are developing a new biologic
immunoassay specifically for the determination of plasmino-
gen-binding lXz-antiplasmin.
In Figure 7, the concentrations of the various inhibitors
ofplasmin and plasminogen in plasma are shown. Plasmin-
ogen (1.5 j-tM) is present in more than twice the concentra-
tion of plasminogen-binding lXz-antiplasmin (0.7 j-tM). Be-
cause systemic effects do occur when >80% of plasminogen-
binding lXz-antiplasmin is consumed, about 35% of the total
plasminogen pool in plasma must be activated to obtain
systemic effects. It would be of interest to measure the rate
of change in the concentration of plasminogen-binding lXZ-
antiplasmin in relation to fibrinogen breakdown during the
course of infusion.
The amount offibrinogenolysis was not reflected by the
results of the total (fibrin and fibrinogen) degradation prod-
ucts. In the patients treated with streptokinase, high levels of
degradation products were found, which is in accordance
with the depletion in fibrinogen in these patients. In the
patients treated with 100 mg of rt-PA, however, low levels of
total degradation products were observed. In an earlier
study (30), we found that the total degradation products
accounted for only 1% of the apparent fibrinogen reduction
when measured by the method of Clauss (37).
Variability in systemic effects. Apart from a clear relation
between the consumption of plasminogen-binding lXZ-
antiplasmin and fibrinogen degradation, other endogenous
factors may also contribute to the variability in systemic
effects. For instance, we observed that the pretreatment
levels of lXz-antiplasmin showed a large variability. This wide
range may, because of the threshold function of plasmino-
gen-binding lXz-antiplasmin, contribute to the variability in
systemic effects. However, the pretreatment values of lXZ-
antiplasmin did not show a significant correlation with fibrin-
ogen consumption. The variability may also be dependent on
the individual levels of the thrombolytic agents in the circu-
lation (20) and the degree of plasminogen activation achieved
in the patient. However, we did not study the individual
levels of the thrombolytic agents.
We observed a significant correlation between the
amount of activated plasminogen and fibrinogen consump-
tion (r = 0.58, p <0.01), as has been previously reported
(11). A significant correlation was also found between plas-
minogen activation and pretreatment levels of plasminogen
(r = 0.76, P <0.001). This is in accordance with the kinetics
of plasminogen activation, which is directly related to plas-
minogen levels in the circulation. In agreement with the
aforementioned correlations, a correlation between pretreat-
ment levels of plasminogen and consumption of fibrinogen
was also detected.
Conclusions. This study provides insight into the variabil-
ity of systemic effects during thrombolytic therapy and
demonstrates the important role of plasminogen-binding
lXz-antiplasmin in the control and prevention of systemic
effects. The clinical significance of the systemic effects is
unknown because it is doubtful whether these effects are
beneficial or disadvantageous in obtaining recanalization, in
the pathogenesis of bleeding and in the occurrence of re-
thrombosis. It is also unclear whether the systemic effects
should be prevented. It can be concluded that to obtain
systemic effects, all plasminogen-binding lXz-antiplasmin (the
most important inhibitor of plasmin in the circulation) must
be overcome. Plasminogen-binding lXz-antiplasmin may,
therefore, be used as a new marker to predict systemic
effects in patients undergoing thrombolytic therapy.
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